Podcast 66: Niacin versus ezetimibe in the face of high cardiovascular risk — a conversation with...

One of the more intriguing pieces of research presented at the American Heart Association this week (and simultaneously released online in the New England Journal of Medicine) shows that extended-release niacin outperforms ezetimibe in high-risk patients. We talk with Dr. Allen J. Taylor, the study’s first author. Contact us at 1-617-440-4374 or write [email protected]. This edition’s links: Interview Link: • Extended-Release Niacin Outperforms Ezetimibe in Lowering Cardiovascular Risk (http://firstwatch.jwatch.org/cgi/cont...) News Links: • USPSTF Recommends Against Routine Mammography for Women in Their 40s (http://firstwatch.jwatch.org/cgi/cont...) • ACOG Releases New Cervical Screening Guidelines into Politically Charged Environment (http://firstwatch.jwatch.org/cgi/cont...) • FDA Approves New Treatment for Shingles-Related Pain (http://firstwatch.jwatch.org/cgi/cont...) (https://www.addtoany.com/add_to/faceb...) (https://www.addtoany.com/add_to/twitt...) (https://www.addtoany.com/add_to/linke...) (https://www.addtoany.com/add_to/email...) (https://www.addtoany.com/share#url=ht...) The post Podcast 66: Niacin versus ezetimibe in the face of high cardiovascular risk — a conversation with the ARBITER 6-HALTS trialist Allen Taylor (https://podcasts.jwatch.org/index.php...) first appeared on Clinical Conversations (https://podcasts.jwatch.org) .